A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Public ClinicalTrials.gov record NCT00781911. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Study identification
- NCT ID
- NCT00781911
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 43 participants
Conditions and interventions
Conditions
Interventions
- Cixutumumab Biological
- depot octreotide Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2009
- Primary completion
- Jun 30, 2011
- Completion
- Apr 30, 2016
- Last update posted
- Sep 19, 2019
2009 – 2016
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Los Angeles | California | 90033 | — |
| ImClone Investigational Site | Los Angeles | California | 90095 | — |
| ImClone Investigational Site | Aurora | Colorado | 80045 | — |
| ImClone Investigational Site | Atlanta | Georgia | 30318 | — |
| ImClone Investigational Site | Indianapolis | Indiana | 46202 | — |
| ImClone Investigational Site | Kenner | Louisiana | 70065 | — |
| ImClone Investigational Site | Columbus | Ohio | 43210 | — |
| ImClone Investigational Site | Providence | Rhode Island | 02903 | — |
| ImClone Investigational Site | Nashville | Tennessee | 37232 | — |
| ImClone Investigational Site | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00781911, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 19, 2019 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00781911 live on ClinicalTrials.gov.